Is SVR4 Testing an Acceptable Alternative Measure of HCV Cure in Re-Treated Patients Following DAA Failure? An SVR4/12 Concordance Evaluation From the POLARIS Clinical Trials

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Is SVR4 Testing an Acceptable Alternative Measure of HCV Cure in Re-Treated Patients Following DAA Failure? An SVR4/12 Concordance Evaluation From the POLARIS Clinical Trials

	AASLD 2025 Nov 7-11 Wash DC Marc Bourlière